Liquidia Corporation (NASDAQ:LQDA – Get Free Report) insider Rajeev Saggar sold 50,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $74.06, for a total transaction of $3,703,000.00. Following the sale, the insider directly owned 142,265 shares of the company’s stock, valued at $10,536,145.90. The trade was a 26.01% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.
Rajeev Saggar also recently made the following trade(s):
- On Monday, August 17th, Rajeev Saggar sold 29,534 shares of Liquidia stock. The shares were sold at an average price of $76.84, for a total transaction of $2,269,392.56.
- On Monday, July 13th, Rajeev Saggar sold 9,926 shares of Liquidia stock. The shares were sold at an average price of $71.51, for a total transaction of $709,808.26.
Liquidia Stock Up 1.3%
LQDA stock traded up $1.00 during mid-day trading on Wednesday, hitting $75.33. 1,155,908 shares of the company were exchanged, compared to its average volume of 1,795,268. The firm has a fifty day simple moving average of $79.15 and a 200 day simple moving average of $55.70. The company has a market capitalization of $6.74 billion, a PE ratio of 54.99 and a beta of 0.58. Liquidia Corporation has a twelve month low of $21.15 and a twelve month high of $93.61. The company has a current ratio of 2.31, a quick ratio of 2.12 and a debt-to-equity ratio of 0.63.
Analyst Upgrades and Downgrades
Several analysts have issued reports on LQDA shares. Wells Fargo & Company upped their price objective on Liquidia from $62.00 to $108.00 and gave the company an “overweight” rating in a research note on Thursday, August 13th. Piper Sandler set a $129.00 target price on Liquidia in a research report on Friday, July 24th. HC Wainwright set a $36.00 price target on Liquidia in a report on Friday, July 24th. Stephens set a $130.00 price target on Liquidia in a research report on Friday, July 24th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Liquidia in a research note on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $98.08.
View Our Latest Stock Report on LQDA
Institutional Investors Weigh In On Liquidia
A number of institutional investors have recently modified their holdings of LQDA. Northwestern Mutual Wealth Management Co. acquired a new stake in Liquidia during the fourth quarter worth about $25,000. NewEdge Advisors LLC acquired a new position in Liquidia in the second quarter valued at approximately $25,000. Covestor Ltd boosted its position in Liquidia by 41.9% during the 4th quarter. Covestor Ltd now owns 1,216 shares of the company’s stock valued at $42,000 after purchasing an additional 359 shares during the period. Tower Research Capital LLC TRC grew its stake in Liquidia by 281.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,679 shares of the company’s stock worth $83,000 after buying an additional 4,927 shares during the last quarter. Finally, Globeflex Capital L P bought a new position in Liquidia during the 2nd quarter worth $175,000. Institutional investors own 64.54% of the company’s stock.
Liquidia Company Profile
Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.
The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).
Read More
- Five stocks we like better than Liquidia
- Bloom Energy’s AI Surge Meets a Valuation Reality Check
- Target Is Winning Shoppers Back—Can the Rally Reach $180?
- IonQ’s Space Contract Points to a New Frontier for Quantum Investors
- Is Apple’s AI Strategy Smarter Than Skeptics Think?
Receive News & Ratings for Liquidia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liquidia and related companies with MarketBeat.com's FREE daily email newsletter.
